Keen et al. suggest that it would be useful to perform controlled therapeutic trials of bromocriptine (a dopamine receptor agonist used in the treatment of hyperprolactinemia) in the case of patients with psoriasis, especially in the case of those with severe forms, even if the prolactin level is normal [84]. The gene discussed is PRL; the disease is hyperprolactinemia.